Posted by Michael Wonder on 25 Mar 2019
Pharma fears “lack of focus” on no-deal Brexit preparations
22 March 2019 - As Brexit is delayed, pharma suggests new measures to avoid no-deal drugs shortages.
The short Brexit extension granted to the UK by the European Council last night averts a no-deal exit next week, but urgent action is still needed to safeguard the medicines supply.
That is the view of Merck KGaA chief executive and President of European pharma's EFPIA, Stefan Oschmann, who says that the pharma industry has “been concerned by a certain lack of focus, outside of our industry, on protecting medicines supply,” as well as the EU’s stance of leaving some critical issues to be resolved by the EU member states.
